Common antibiotic cefepime tied to 94% higher death risk, study finds

Key Points:

• A new global study published in JAMA Network Open found that the antibiotic cefepime is associated with a higher risk of all-cause mortality compared to other beta-lactam antibiotics, with a 94.4% probability of increased death risk across 110 clinical trials involving over 22,000 patients.
• The increased mortality risk was more pronounced in adults, particularly those treated for febrile neutropenia, a serious condition involving fever and low white blood cell counts, though the study did not establish causation.
• Researchers suggested that challenges in dosing cefepime—where both underdosing and overdosing could contribute to poorer outcomes—may explain the association, emphasizing the need for further research and better dosing guidelines.
• Despite the findings, cefepime remains widely used due to its broad-spectrum effectiveness, and experts recommend continued use with caution rather than discontinuation.
• Medical analysts highlighted the complexity of interpreting the data, noting that patient conditions and dosing variations complicate conclusions, and suggested that advanced tools like AI could help optimize dosing to improve safety and outcomes.